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Abstract
Introduction The Oncotype DX assay was recently reported to
predict risk for distant recurrence among a clinical trial
population of tamoxifen-treated patients with lymph node-
negative, estrogen receptor (ER)-positive breast cancer. To
confirm and extend these findings, we evaluated the
performance of this 21-gene assay among node-negative
patients from a community hospital setting.
Methods A case-control study was conducted among 4,964
Kaiser Permanente patients diagnosed with node-negative
invasive breast cancer from 1985 to 1994 and not treated with
adjuvant chemotherapy. Cases (n = 220) were patients who
died from breast cancer. Controls (n = 570) were breast cancer
patients who were individually matched to cases with respect to
age, race, adjuvant tamoxifen, medical facility and diagnosis
year, and were alive at the date of death of their matched case.
Using an RT-PCR assay, archived tumor tissues were analyzed
for expression levels of 16 cancer-related and five reference
genes, and a summary risk score (the Recurrence Score) was
calculated for each patient. Conditional logistic regression
methods were used to estimate the association between risk of
breast cancer death and Recurrence Score.
Results After adjusting for tumor size and grade, the
Recurrence Score was associated with risk of breast cancer
death in ER-positive, tamoxifen-treated and -untreated patients
(P = 0.003 and P = 0.03, respectively). At 10 years, the risks for
breast cancer death in ER-positive, tamoxifen-treated patients
were 2.8% (95% confidence interval [CI] 1.7–3.9%), 10.7%
(95% CI 6.3–14.9%), and 15.5% (95% CI 7.6–22.8%) for
those in the low, intermediate and high risk Recurrence Score
groups, respectively. They were 6.2% (95% CI 4.5–7.9%),
17.8% (95% CI 11.8–23.3%), and 19.9% (95% CI 14.2–
25.2%) for ER-positive patients not treated with tamoxifen. In
both the tamoxifen-treated and -untreated groups, approximately
50% of patients had low risk Recurrence Score values.
Conclusion In this large, population-based study of lymph node-
negative patients not treated with chemotherapy, the
Recurrence Score was strongly associated with risk of breast
cancer death among ER-positive, tamoxifen-treated and -
untreated patients.
Introduction
Approximately 65% of women currently diagnosed with inva-
sive breast cancer have lymph node-negative disease at diag-
nosis [1], and 85% of these women are expected to be alive
and free from distant metastasis at 10 years [2]. Chemother-
apy in this group of patients, especially among patients with
estrogen receptor (ER)-positive disease treated with adjuvant
hormonal therapy, offers only a modest improvement in 10-
year survival [2,3]. Nonetheless, according to current guide-
lines the majority of node-negative breast cancer patients
CI = confidence interval; ER = estrogen receptor; NSABP = National Surgical Adjuvant Breast and Bowel Project; PgR = progesterone receptor; 
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should be considered for chemotherapy [4-6]. This is largely
because of our limited ability to identify those individual
patients who are unlikely to benefit from such treatment.
Multigene assays may provide information on patient progno-
sis and response to therapy that is superior and/or comple-
mentary to that from standard histopathological and
immunohistochemical techniques [7,8]. However, multiple
well conducted and controlled observational studies or clinical
trials in independent populations are needed to establish the
clinical usefulness of these assays [9,10].
Using a multistep approach, a 21-gene assay (Oncotype DX)
was recently developed for use in paraffin-embedded tumor
tissue to predict risk for distant recurrence or death in lymph
node-negative breast cancer patients [11]. Approximately 250
genes, selected from the published literature, genomic data-
bases, pathway analysis, and from microarray-based gene
expression profiling experiments performed using fresh frozen
tissue, were considered as candidates. The final gene list (16
cancer-related and five reference genes) and summary score
(Recurrence Score) algorithm for this assay (Figure 1) were
developed by analyzing the results of three independent pre-
liminary breast cancer studies (that is, training sets) con-
ducted in a total of 447 patients [12].
Two subsequent studies were conducted to evaluate the per-
formance of the Recurrence Score in predicting distant recur-
rence-free survival in lymph node-negative breast cancer
patients not treated with chemotherapy. Among 668
tamoxifen-treated patients in the National Surgical Adjuvant
Breast and Bowel Project (NSABP) B-14 clinical trial [12], the
Recurrence Score was strongly predictive of risk for distant
recurrence, both alone and in multivariate analyses that also
included patient age, tumor size, tumor grade, and ER and
HER2 status. For patients categorized as low, intermediate, or
high risk based on Recurrence Score, the Kaplan-Meier esti-
mates for the rates of distant recurrence at 10 years (and the
associated 95% confidence intervals [CIs]) were 6.8% (95%
CI 4.0–9.6%), 14.3% (95% CI 8.3–20.3%), and 30.5% (95%
CI 23.6–37.4%), respectively. A second study [13] evaluated
the assay among 149 patients not treated with adjuvant ther-
apy (hormonal or chemotherapy) at the MD Anderson Cancer
Center; it found no clear association between the Recurrence
Score and risk for distant recurrence. Rates of distant recur-
rence at 10 years were 18% (95% CI 7–30%), 38% (95% CI
15–61%), and 28% (95% CI 13–32%) for the low, intermedi-
ate, and high risk categories, respectively.
To evaluate the Oncotype DX assay in a third independent
study population of lymph node-negative breast cancer
patients not treated with chemotherapy, we conducted a case-
control study among a large population of women who were
diagnosed and treated at 14 hospitals and clinics within the
Northern California Kaiser Permanente health plan. A pre-
specified primary aim of the study was to assess the degree to
which the Recurrence Score would predict the risk of breast
cancer-specific mortality among women with ER-positive,
node-negative breast cancer treated with tamoxifen (that is,
patients clinically similar to those included in the study con-
ducted by Paik and coworkers [12]), either alone or in multivar-
iate analyses with tumor size and tumor grade. A pre-specified
secondary aim was to examine the extent to which the Recur-
rence Score predicts risk of breast cancer-specific mortality
among ER-positive, node-negative patients not treated with
tamoxifen. A pre-specified exploratory aim was to examine the
association between risk of breast cancer death and Recur-
rence Score among node-negative, ER-negative patients.
Materials and methods
Study population and design
We conducted a case-control study nested within a cohort of
breast cancer patients. The Northern California Kaiser Perma-
nente tumor registry, a contributor to the Surveillance, Epide-
miology, and End Results (SEER) program of cancer
registries, was used to identify all female health plan members
who were diagnosed with lymph node-negative invasive breast
cancer from 1985 to 1994. Northern California Kaiser Perma-
nente is a nonprofit, integrated health services delivery organ-
ization that provides care for over 3 million members at 14
Northern California Kaiser hospitals and 23 outpatient clinics.
The Kaiser Permanente membership is racially and ethnically
diverse and is demographically similar to the general popula-
tion of northern California, although it tends to under-represent
the extremes of the socioeconomic spectrum [14-16]. The
study was approved by the Kaiser Permanente Institutional
Review Board.
Breast cancer patients were eligible if their nodal status was
documented to be negative by pathologic assessment, they
were diagnosed before age 75 years, and their initial disease
was not treated with chemotherapy. Patients were excluded
for the following reasons: inflammatory or bilateral breast can-
cer or evidence of metastasis (including lymph nodes) at initial
diagnosis; prior invasive cancer (breast or other) at diagnosis;
or unknown/unconfirmed treatment with tamoxifen.
Using the Kaiser Permanente tumor registry and electronic
membership databases, patients were followed until death
due to breast cancer, death from another cause, bilateral
breast cancer, termination of membership, or December
2002, whichever came first.
Cases were patients whose first event was death from breast
cancer. At each case's death, up to three controls were ran-
domly selected from patients alive and under follow up (that is,
incidence density sampling) [17]. Controls were individually
matched to their case with respect to age (within 1 year), race
(non-Hispanic white, Hispanic, Black, Asian), calendar year of
diagnosis (exact year), Kaiser Permanente pathology depart-Available online http://breast-cancer-research.com/content/8/3/R25
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ment of origin, and treatment of index breast cancer with
tamoxifen (yes, no). Note that matching on tamoxifen treatment
maximized our ability to conduct analyses stratified by
tamoxifen treatment. Not matching on tumor size or tumor
grade allowed us to examine whether these measures provide
information on risk of breast cancer death that is independent
of Recurrence Score. Matching requirements were relaxed to
find up to three eligible controls per case. Matching criteria
Table 1
Selected characteristics of the study population
Characteristic Cases (n = 220) Controls (n = 570)
Matched variables
Age at diagnosis (years)
< 4 0 1 7( 8 % )2 3( 4 % )
40–49 42 (19%) 127 (22%)
50–59 64 (29%) 152 (27%)
60–74 97 (44%) 268 (47%)
Race/ethnicity
White, non-Hispanic 172 (78%) 457 (80%)
White, Hispanic 7 (3%) 13 (2%)
B l a c k 2 0( 9 % )4 7( 8 % )
Asian 21 (10%) 53 (9%)
Surgery year
1985–1989 146 (66%) 385 (68%)
1990–1994 74 (34%) 185 (32%)
Adjuvant tamoxifen
No 156 (71%) 393 (69%)
Yes 64 (29%) 177 (31%)
Unmatched variables
ER status from RT-PCR1
Positive 168 (76%) 514 (90%)
Negative 52 (24%) 56 (10%)
Tumor size (cm)
≤1 49 (22%) 193 (34%)
1.1–2 93 (42%) 255 (45%)
2.1–4 72 (33%) 114 (20%)
>4 6 (3%) 8 (1%)
Tumor grade (differentiation)2
Well 25 (11%) 175 (31%)
Moderate 92 (42%) 261 (46%)
Poor 103 (47%) 134 (23%)
Recurrence Score
Low risk (<18) 57 (26%) 322 (56%)
Intermediate risk (18–30) 54 (25%) 108 (19%)
High risk (≥31) 109 (50%) 140 (25%)
1Cutoff points based on RT-PCR values: ≤6.5 and >6.5 units. 2Bloom-Richardson grading criteria, pathologist 1. ER, estrogen receptor; RT-PCR, 
reverse transcription polymerase chain reaction.Breast Cancer Research    Vol 8 No 3    Habel et al.
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were relaxed in the following order: age was relaxed to < 50
versus ≥ 50 years; calendar year of diagnosis was relaxed to
± 1 year; calendar year of diagnosis was relaxed to ± 2 years;
and pathology facility was dropped as a matching factor.
The medical records of cases and controls were reviewed to
confirm the initial diagnosis, treatment and cause of death, and
to obtain information on eligibility criteria. Pathologic tumor
size was obtained from pathology reports. Information on ER
and progesterone receptor (PgR) status of the index tumor
(usually assessed by the ligand-binding assay) was also
abstracted from the medical record.
Cases and controls were selected and eligibility was deter-
mined before laboratory measurement of gene expression. Of
the 402 cases identified as potentially eligible by the tumor
registry, 269 were determined to be eligible by chart review.
The eligibility of 27 cases could not be determined because of
incomplete or unavailable medical records and were consid-
ered lost to the study. Similarly, 722 of the 989 controls initially
matched to eligible cases were determined to be eligible by
chart review and the eligibility of 29 could not be determined.
Of those eligible by chart review, 31 cases and 91 controls
were lost because of missing tumor blocks. Another four
cases were lost because we were unable to find at least one
matched control. This left 234 cases and 631 controls availa-
ble for pathology studies.
Blinding and batching of pathology and laboratory 
procedures
All pathology and laboratory procedures (slide review, section-
ing of tumor blocks, macro-dissection, RT-PCR assays, and
Recurrence Score calculations) were conducted blinded to
the case-control status of patient specimens. In addition, all
batches of pathology materials sent to Kaiser Permanente
Regional Laboratory, NSABP Pathology, and Genomic Health,
Inc. included a mixture of cases and controls.
Sample preparation
For eligible cases and controls, the hematoxylin and eosin
stained slides from biopsies and/or surgeries performed at the
time of the index diagnosis were reviewed using pre-specified
criteria in order to identify the most representative block and to
evaluate whether sufficient tumor tissue was present. Speci-
mens with no tumor or very little tumor (<5% of the area occu-
pied by invasive cancer cells compared to the area occupied
by other epithelial elements, such as normal epithelium, fibro-
cystic change, or ductal or lobular carcinoma in situ) were
excluded from the study (n = 18). Specimens with regions on
the slide having prominent nontumor elements (such as
smooth muscle, hemorrhage, fibrosis, hyperplastic epithelium,
and/or normal breast; but not ductal or lobular carcinoma in
situ or necrosis) where the nontumor elements were both suf-
ficiently localized to be amenable to macro-dissection and suf-
ficiently abundant (>50% of the overall tissue on the slide)
were sent to NSABP Pathology for macro-dissection (n = 59).
Macro-dissection to obtain enriched tumor tissue was per-
Table 2
Distributions of tumor size and tumor grade in Recurrence Score categories for all 220 cases and 570 controls
Variable (number of patients) Recurrence Score
< 18
(n = 379)
18–30
(n = 162)
≥30
(n = 249)
Correlation1 
(P value)
Tumor size (cm) 0.25 (<0.0001)
≤1 (n = 242) 147 (61%) 51 (21%) 44 (18%)
1.1–2 (n = 348) 173 (50%) 65 (19%) 110 (32%)
2.1–4 (n = 186) 55 (30%) 44 (24%) 87 (47%)
>4 (n = 14) 4 (29%) 2 (14%) 8 (57%)
Tumor grade pathologist 1 0.54 (<0.0001)
Well (n = 200) 146 (73%) 44 (22%) 10 (5%)
Moderate (n = 353) 199 (56%) 90 (25%) 64 (18%)
Poor (n = 237) 34 (14%) 28 (12%) 175 (74%)
Tumor size and grade 0.42 (<0.0001)
≤2 cm and well or ≤1 cm and moderate 
(n = 285)
204 (72%) 60 (21%) 21 (7%)
>2 cm and well, or 1.1–2 cm and 
moderate, or ≤2 cm and poor (n = 330)
143 (41%) 63 (19%) 133 (40%)
>2 cm and moderate/poor (n = 175) 41 (23%) 39 (22%) 95 (54%)
1Spearman rank correlationAvailable online http://breast-cancer-research.com/content/8/3/R25
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formed using a safety blade cleaned with RNaseZAP (Ambion,
Austin, TX, USA) by NSABP Pathology on six (10 µm) sec-
tions of the region enriched in tumor tissue. For all other spec-
imens, three (10 µm) sections were prepared by Kaiser
Permanente Regional Laboratory, placed into a microcentri-
fuge tube, and sent to Genomic Health, Inc.
Tumor size, grade, and estrogen receptor status
When not recorded on the pathology report (7% of reports),
tumor size was obtained from a pathology review of all hema-
toxylin and eosin stained slides from all surgeries at diagnosis.
Tumor grade, based on review of an hematoxylin and eosin
slide from the most representative block, was assessed inde-
pendently by two board certified (in anatomic and clinical
pathology), assistant professors in departments of pathology,
using the modified Bloom-Richardson grading criteria [18]. ER
status of the index tumor was unavailable in the 10- to 20-year-
old medical record for a significant proportion of patients
(16%), and therefore all tumors were classified as positive or
negative based on ER expression by RT-PCR (>6.5 and ≤6.5,
respectively; cutoff points based on prior studies examining
correlation of RT-PCR with immunohistochemistry)
[11,13,19]. In our study population, the concordance of ER
status from RT-PCR versus from medical chart information
was moderate (kappa 0.49, 95% CI 0.41–0.56). All but seven
(out of a total of 122) of the discordances were patients clas-
sified as ER positive based on RT-PCR and ER negative
based on information in the medical chart.
RT-PCR assay of gene expression and calculation of the 
Recurrence Score
Gene expression analysis in fixed paraffin-embedded tumor
tissue was performed by Genomic Health, Inc., as described
previously [11,12]. Briefly, after RNA extraction and DNase I
treatment, total RNA content was measured and the absence
of DNA contamination was verified. Reverse transcription was
performed followed by quantitative RT-PCR reactions in 384
well plates using Applied Biosystems PRISM®  7900 HT
instruments (Applied Biosystems, Foster City, CA, USA).
Expression of each gene was measured in triplicate wells, and
then normalized relative to a set of five reference genes (β-
actin, GAPDH, GUS, RPLPO, and TFRC). Reference-normal-
ized expression measurements range from 0 to 15, where a 1-
unit increase reflects approximately a twofold increase in RNA.
The potential impact of tumor heterogeneity on Recurrence
Score results was examined in two small studies (unpublished
data). In a study of 20 patients and 60 blocks (two to five
blocks/patient), analysis of variance was used to examine the
variability of Recurrence Score between blocks from the same
patient (tissue sections did not undergo macro-dissection).
The standard deviation in Recurrence Scores (as a continuous
value) between blocks was 3.0 Recurrence Score units. For
16 of the 20 patients, the standard deviation between blocks
was less than 2.5 Recurrence Score units. A similarly high
concordance (Pearson's r  = 0.86) was also observed
between Recurrence Score results from core biopsies and
resections among 49 patients with locally advanced breast
cancer.
Recurrence Score cutoff points were pre-specified and classi-
fied patients into low risk (Recurrence Score <18), intermedi-
ate risk (Recurrence Score 18–30) and high risk (Recurrence
Score ≥31) categories. All methods used for measurement of
gene expression levels and for the calculation of Recurrence
Score and gene group scores were identical to those used in
the study conducted by Paik and coworkers [12].
Statistical analysis
Statistical analyses were conducted entirely by Kaiser Perma-
nente researchers following a pre-specified plan. As specified,
results were generated for patient groups, based on ER status
and tamoxifen treatment.
The Recurrence Score was examined as a continuous variable
in 50-unit increments, for consistency and comparison with
previously published Recurrence Score findings. In additional
analyses, women were categorized into presumptive low,
intermediate, and high risk groups based on cutoff points
(Recurrence Score < 18, 18–30 and ≥31, respectively), and
when categorized according to Recurrence Score quartiles.
When examining the relationships between risk of breast can-
cer death and the expression level of individual genes, the
expression levels were treated as continuous variables. When
examining gene groups, the proliferation gene group and the
HER2 gene group scores were treated as continuous varia-
bles both with and without transformation based on a thresh-
old value (see the Recurrence Score algorithm in Figure 1).
Tumor size was examined both as a continuous variable in 2
cm units (for consistency with the NSABP B-14 study [12])
and when categorized as ≤1 cm, 1.1–2 cm, 2.1–4 cm, and >4
cm. Tumor grade was examined as a categorical variable (well
differentiated, moderately differentiated, and poorly differenti-
ated). The grading used was from the standardized re-review.
We examined tumor grade separately for pathologist 1 and
pathologist 2.
Conditional logistic regression was used to calculate odds
ratios as estimates of the relative risks for breast cancer death
associated with the Recurrence Score, or a component of the
Recurrence Score (univariate analyses). In addition, we esti-
mated relative risks adjusted for tumor size and tumor grade
(multivariate analyses). Model parameter estimation was done
by maximum likelihood, and 95% Wald's confidence limits
were calculated. Statistical significance was assessed via the
likelihood ratio test [20]. In multivariate analyses, reported PBreast Cancer Research    Vol 8 No 3    Habel et al.
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values are for the addition of the given factor to a model includ-
ing all other factors.
For women with ER-positive tumors, analyses were performed
separately for those treated and not treated with tamoxifen.
Because ER status was not a matching factor but was associ-
ated with our outcome, fewer than half of the ER-negative
cases (n = 16) had matched controls who were also ER-neg-
ative. We therefore conducted conditional logistic regression
analyses among those patients not treated with tamoxifen and
generated relative risk estimates for ER-negative patients
using terms for interaction with ER status. Finally, we con-
ducted analyses of the full study population, using conditional
logistic regression and interaction terms for ER status and
tamoxifen therapy to obtain relative risk estimates for the differ-
ent pre-specified patient groups characterized by these fac-
tors. However, because results were not materially different,
we present only those results from analyses conducted within
patient groups.
Methods developed by Langholz and Borgan [21] for nested
case-control data were used to estimate the absolute risk of
breast cancer death at 10 years and the corresponding 95%
CIs. Estimates were calculated for subgroups of ER-positive
patients, stratified on tamoxifen treatment and on Recurrence
Score, tumor size, and tumor grade. In addition, 10-year risks
for breast cancer death were calculated for subgroups of
patients, when cross-classified by tumor size and grade and by
Recurrence Score and tumor size and grade. The original
Langholz and Borgan estimator assumed simple random sam-
pling of controls from the set of known eligibles. In this study,
we could not confirm eligibility without a review of the medical
records, and therefore we sampled potentially eligible controls
until up to three were confirmed for study inclusion. Thus, a
slight modification to the original absolute risk estimator was
necessary in order to reflect our sampling scheme (Additional
file 1).
For comparison with the absolute risk estimates in the Kaiser
population, the NSABP provided us with the Kaplan-Meier
estimates for the probability of breast cancer death at 10 years
among the 668 NSABP B-14 [12] tamoxifen-treated patients
with node-negative breast cancer (previously published
results included estimates for distant recurrence, relapse-free
survival, and overall survival).
Results
Characteristics of cases and controls
Among 4,964 potentially eligible lymph node-negative invasive
breast cancer patients, we identified 234 eligible cases and
selected 631 controls with available tumor blocks. After loss
of 7.9% of specimens because of insufficient tumor and 1%
because of failed RT-PCR analysis, a total of 220 cases and
570 controls were available for statistical analyses. A total of
142 cases (64.6%) had three controls each, 66 cases
Figure 1
Twenty-one gene panel and calculation of recurrence score Twenty-one gene panel and calculation of recurrence score. (a) The 
final gene list (16 cancer-related and five reference genes) and sum-
mary score (Recurrence Score) algorithm for this assay were devel-
oped by analyzing the results of three independent preliminary breast 
cancer studies (that is, training sets) with a total of 447 patients [11]. 
The Recurrence Score, on a scale from 0 to 100, is derived from the 
reference-normalized expression measurements in four steps. In the 
first step the expression for each gene is normalized relative to the 
expression of the five reference genes (b-actin, GAPDH, GUS, RPLPO, 
and TFRC). Reference-normalized expression measurements range 
from 0 to 15, where a 1-unit increase reflects approximately a twofold 
increase in RNA. (b) In the second step the HER2 Group Score, the 
ER Group Score, the Proliferation Group Score, and the Invasion 
Group Score are calculated from individual gene expression measure-
ments. (c) In the third step the Recurrence Score unscaled (RSU) is 
calculated using coefficients that were pre-defined based on regres-
sion analysis of gene expression and recurrence in the three training 
studies (Providence, Rush, and NSABP B-20 [12]). A plus sign indi-
cates increased expression is associated with increased recurrence 
risk. A minus sign indicates that increased expression is associated 
with decreased recurrence risk.Available online http://breast-cancer-research.com/content/8/3/R25
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(30.0%) had two controls each, and 12 cases (5.5%) had one
control each. The distribution of factors available from the
tumor registry (age, tumor size, race, diagnosis year, ER sta-
tus, and tamoxifen treatment) among the evaluable cases and
controls was generally similar to the distribution of these fac-
tors among the 239 potentially eligible cases and controls
who were lost to the study. However, both lost cases and lost
controls were slightly more likely than evaluable patients to be
younger, to be not white, or to have smaller tumors.
Breast cancer deaths occurred a median of 4.9 years after
diagnosis. Among the cases and controls, the median tumor
size was 1.5 cm (range 0.2–7.0 cm). Cases and controls were
similar with respect to matching factors including age, race,
diagnosis year, and treatment with tamoxifen (Table 1). Nearly
three-quarters of the study population was aged 50 years or
older at diagnosis (median age 58 years) and about 80% were
non-Hispanic white. Approximately two-thirds of patients were
diagnosed with their breast cancer during the first 5 years of
the accrual period (1985–1989). Overall, one-third of patients
were treated with adjuvant tamoxifen. Before 1989, 11% of
patients were treated with tamoxifen; from 1989 to 1994,
58% of patients were treated with tamoxifen. Among those
treated with tamoxifen, the median duration was 4 years;
approximately 10% had a year of treatment or less. Compared
with controls, cases more commonly had tumors that were ER
negative, larger, or more poorly differentiated. Cases were also
more likely to have tumors with higher Recurrence Score val-
ues. Approximately 50% of patients had Recurrence Score
values in the low risk category (that is, Recurrence Score
<18).
For pre-specified analyses stratified by ER status and
tamoxifen therapy, there were 55 cases and 150 matched
Table 3
Relative risks associated with recurrence score among ER-positive patients, stratified by treatment with tamoxifen
Score Cases Controls RR1 (95% CI) P value
Tamoxifen treated (55 cases and 150 controls)
Recurrence Score
Continuous2 55 (100%) 150 (100%) 7.6 (2.6–21.9) <0.0001
Pre-specified categories
Low risk (<18) 16 (29%) 95 (63%) 1.0 reference
Intermediate risk (18–30) 22 (40%) 35 (23%) 4.0 (1.8–8.8)
High risk (≥31) 17 (31%) 20 (13%) 6.2 (2.4–15.8)
Quartiles3 0.0004
1st (0–8.25) 5 (9%) 38 (25%) 1.0 reference
2nd (8.26–14.43) 6 (11%) 37 (25%) 1.0 (0.3–3.7)
3rd (14.44–20.95) 15 (27%) 38 (25%) 2.9 (1.0–8.9)
4th (20.96–78.78) 53 (53%) 37 (25%) 5.8 (2.0–16.6)
Tamoxifen untreated (110 cases and 251 controls)
Recurrence Score
Continuous2 110 (100%) 251 (100%) 4.1 (2.1–8.1) <0.0001
Pre-specified categories <0.0001
Low risk (<18) 40 (36%) 160 (64%) 1.0 reference
Intermediate risk (18–30) 32 (29%) 47 (19%) 2.7 (1.5–5.0)
High risk (≥31) 38 (35%) 44 (18%) 3.3 (1.8–5.9)
Quartiles4 <0.0001
1st (0–7.53) 11 (10%) 63 (25%) 1.0 reference
2nd (7.54–14.25) 19 (17%) 64 (25%) 1.5 (0.7–3.4)
3rd (14.26–21.86) 23 (28%) 62 (25%) 2.1 (0.9–4.9)
4th (21.87–85.82) 57 (52%) 62 (25%) 5.3 (2.5-1.3)
1Conditional logistic regression models include Recurrence Score variables only. 2Relative risks for Recurrence Score calculated with regard to an 
increment of 50 units (chosen to be consistent with and comparable with previous studies). 3Quartiles based on distribution among controls treated 
with tamoxifen. 4Quartiles based on distribution among controls not treated with tamoxifen. CI, confidence interval; ER, estrogen receptor; RR, 
relative risk.Breast Cancer Research    Vol 8 No 3    Habel et al.
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controls who were tamoxifen treated and had ER-positive
tumors according to RT-PCR assay. There were 110 cases
and 251 matched controls who had ER-positive tumors
according to RT-PCR assay and were not treated with
tamoxifen. There were 16 cases with matched controls (n =
19) who had ER-negative tumors according to RT-PCR assay
and were not treated with tamoxifen (out of a total of 52 ER-
negative cases and 56 ER-negative controls). In addition, a
Table 4
Relative risks of breast cancer death associated with tumor size, grade, and recurrence score among ER-positive patients, stratified 
by treatment with tamoxifen
Score Cases Controls RR 95% CI P value
Tamoxifen treated (55 cases and 150 controls)
Multivariate analyses without 
Recurrence Score1
Tumor size (cm) 0.009
Continuous2 55 (100%) 150 (100%) 2.6 (1.2–5.5)
Grade (pathologist 1) 0.007
Well 6 (11%) 50 (33%) 1.0 reference
Moderate 28 (51%) 69 (46%) 2.8 (1.1–7.4)
Poor 21 (38%) 31 (21%) 4.5 (1.6–12.3)
Multivariate analyses with Recurrence Score3
Tumor size (cm) 0.013
Continuous2 55 (100%) 150 (100%) 2.5 (1.2–5.4)
Grade (pathologist 1) 0.126
Well 6 (11%) 50 (33%) 1.0 reference
Moderate 28 (51%) 69 (46%) 2.4 (0.9–6.4)
Poor 21 (38%) 31 (21%) 2.8 (0.9–9.3)
Recurrence Score 0.003
Continuous4 55 (100%) 150 (100%) 5.3 (1.6–17.2)
Tamoxifen untreated (110 cases and 251 controls)
Multivariate analyses without Recurrence Score1
Tumor size (cm) 0.035
Continuous2 110 (100%) 251 (100%) 1.8 (1.0–3.1)
Grade (pathologist 1) <0.001
Well 17 (15%) 83 (33%) 1.0 reference
Moderate 54 (49%) 131 (52%) 2.0 (1.1–3.6)
Poor 39 (35%) 37 (15%) 4.7 (2.3–9.9)
Multivariate analyses with Recurrence Score3
Tumor size (cm) 0.036
Continuous2 110 (100%) 251 (100%) 1.8 (1.0–3.1)
Grade (pathologist 1) 0.018
Well 17 (15%) 83 (33%) 1.0 reference
Moderate 54 (49%) 131 (52%) 1.8 (1.0–3.4)
Poor 39 (35%) 37 (15%) 3.2 (1.4–7.2)
Recurrence Score 0.025
Continuous4 110 (100%) 251 (100%) 2.4 (1.1–5.2)
1Conditional logistic regression models include tumor size and tumor grade only. 2Relative risks for tumor size calculated with regard to an 
increment of 2 cm. 3Conditional logistic regression models include tumor size, tumor grade, and Recurrence Score. 4Relative risks for Recurrence 
Score calculated with regard to an increment of 50 units (chosen to be consistent with and comparable to previous studies). CI, confidence interval; 
ER, estrogen receptor; RR, relative risk.Available online http://breast-cancer-research.com/content/8/3/R25
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small number of ER-negative patients were treated with
tamoxifen (nine cases and three controls).
Distribution of Recurrence Score risk categories by 
tumor size and tumor grade
The distributions of tumor size and/or tumor grade in patients
categorized on the basis of the Recurrence Score as low risk
(Recurrence Score <18), intermediate risk (Recurrence Score
18–30), or high risk (Recurrence Score ≥31) are shown in
Table 2. The Recurrence Score was associated with tumor
size and even more so with tumor grade. Nonetheless, a
number of patients had large (>2 cm) and/or moderately or
poorly differentiated tumors with low risk Recurrence Score
values. In addition, a small percentage had small (≤1 cm) and/
or well differentiated tumors with high risk Recurrence Score
values. The concordance in the assessment of tumor grade
between the two pathologists was moderate (kappa 0.53,
95% CI 0.49–0.59).
Relative risks for breast cancer death: ER-positive 
patients
In ER-positive patients treated with tamoxifen, the risk of
breast cancer death was positively and strongly associated
with Recurrence Score when analyzed as a continuous varia-
ble, when categorized into quartiles, or when categorized
based on pre-specified cutoff points (Table 3).
In ER-positive patients not treated with tamoxifen, the risk of
breast cancer death was also positively associated with
Recurrence Score (Table 3). As expected, the association of
Recurrence Score with risk of breast cancer death appeared
to be stronger among ER-positive patients treated with
tamoxifen than among those not treated with tamoxifen.
Larger tumors and higher grade tumors were associated with
an increased risk of breast cancer-specific mortality in both
tamoxifen-treated and -untreated ER-positive patients (Table
4). When the Recurrence Score (continuous) was added to
these multivariate models, it provided information on risk that
was independent of tumor size and tumor grade. This was also
true when the Recurrence Score was categorized into quar-
tiles or when it was categorized based on pre-specified cutoff
points (not shown). Note that even though there were differ-
ences in the assessment of grade between the two patholo-
gists, similar to observations from other studies [22-26], the
results were not materially different when tumor grade assess-
ments from pathologist 2, rather than pathologist 1, were used
(not shown).
Figure 2
Relative risks (RRs) for death associated with expression of single  genes Relative risks (RRs) for death associated with expression of single 
genes. Findings are stratified by tamoxifen treatment and ER status. 
The position of each symbol indicates the RR. The length of the hori-
zontal line through the symbol indicates the 95% CI. The blue boxes 
indicate the RRs and 95% CIs for ER-positive patients treated with 
tamoxifen, the green pyramids indicate the RRs and 95% CIs for ER-
positive patients not treated with tamoxifen, and the red downward 
pointing triangles indicate the RRs and 95% CIs for ER-negative 
patients not treated with tamoxifen. CI, confidence interval; ER, estro-
gen receptor; RR, relative risk.
Figure 3
Relative risks (RRs) of death associated with gene group scores used  in calculation of the Recurrence Score Relative risks (RRs) of death associated with gene group scores used 
in calculation of the Recurrence Score. Findings are stratified by 
tamoxifen treatment and ER status. The position of each symbol indi-
cates the RR. The length of the horizontal line through the symbol indi-
cates the 95% CI. The blue boxes indicate the RRs and 95% CIs for 
ER-positive patients treated with tamoxifen, the green pyramids indi-
cate the RRs and 95% CIs for ER-positive patients not treated with 
tamoxifen, and the red downward pointing triangles indicate the RRs 
and 95% CIs for ER-negative patients not treated with tamoxifen. CI, 
confidence interval; ER, estrogen receptor; RR, relative risk.Breast Cancer Research    Vol 8 No 3    Habel et al.
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Table 5
Ten-year risk of death in relation to Recurrence Score and tumor size and grade among ER-positive patients, stratified by treatment 
with tamoxifen
Risk classifier Cases Controls 10-Year risk
% 95% CI
Tamoxifen treated
Recurrence Score (55 cases and 150 controls)
Low (<18) 29% 63% 2.8 (1.7–3.9)
Intermediate (18–30) 40% 23% 10.7 (6.3–14.9)
High (≥31) 31% 13% 15.5 (7.6–22.8)
Tumor size (55 cases and 150 controls)
≤1 cm 16% 31% 3.6 (1.7–5.5)
1.1–2 cm 44% 43% 5.8 (3.7–7.8)
>2 cm 40% 26% 9.3 (5.5–13.1)
Tumor grade (55 cases and 150 controls)
Well 11% 33% 2.1 (0.7–3.5)
Moderate 51% 46% 6.9 (4.7–9.0)
Poor 38% 21% 9.9 (6.0–13.7)
Tumor size and grade (55 cases and 150 controls)
≤2 cm and well or ≤1 cm and moderate 15% 43% 2.5 (1.2–3.9)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 49% 39% 7.2 (4.9–9.5)
>2 cm and moderate/poor 36% 18% 11.5 (6.6–16.2)
Recurrence Score, tumor size and grade
Recurrence Score low <18 (16 cases and 95 controls)
≤2 cm and well or ≤1 cm and moderate 6% 46% 0.4 (0.0–1.0)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 63% 39% 4.1 (2.0–6.2)
>2 cm and moderate/poor 31% 15% 6.9 (1.8–11.7)
Recurrence Score intermediate 18–30 (22 cases and 35 controls)
≤2 cm and well or ≤1 cm and moderate 32% 51% 6.8 (2.6–10.9)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 45% 29% 21.9 (5.0–35.8)
>2 cm and moderate/poor 23% 20% 13.5 (1.2–24.2)
Recurrence Score high ≥31 (17 cases and 20 controls)
≤2 cm and well or ≤1 cm and moderate 0% 10% 12.2 (0.0–31.0)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 41% 60% 10.9 (2.9–18.3)
>2 cm and moderate/poor 59% 30% 28.9 (7.4–45.3)
Tamoxifen untreated
Recurrence Score (110 cases and 251 controls)
Low (<18) 36% 64% 6.2 (4.5–7.9)
Intermediate (18–30) 29% 19% 17.8 (11.8–23.3)
High (≥31) 35% 18% 19.9 (14.2–25.2)
Tumor size (110 cases and 251 controls)
≤1 cm 29% 39% 8.5 (6.0–10.9)
1.1–2 cm 41% 45% 10.4 (7.8–12.9)
>2 cm 30% 16% 16.4 (11.4–21.0)Available online http://breast-cancer-research.com/content/8/3/R25
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The relationships between the expression of the individual
genes that comprise the Recurrence Score and risk of breast
cancer death were generally similar in tamoxifen-treated and -
untreated ER-positive patients (Figure 2). The risk for death
was positively associated with expression of each of the five
proliferation genes (cyclin B1, Ki-67, MYLBL2, STK15, and
survivin). Positive associations were also observed for genes
in the invasion group. The risk for death was negatively asso-
ciated with expression of the ER-related genes (ER, PgR,
BCL2, and SCUBE2). However, the associations between
expression of the ER-related genes and risk were generally
stronger for the tamoxifen-treated patients, especially with
respect to the quantitative expression of the ER gene. Risk for
death due to breast cancer was not statistically significantly
associated with CD68, HER2, or GRB7 gene expression in
patients treated or untreated with tamoxifen.
The associations between expression of the gene group
scores (as calculated in the Recurrence Score) and risk of
breast cancer death were generally stronger than those for
individual genes (Figure 3).
Relative risks for breast cancer death: ER-negative 
patients
After adjusting for tumor size and tumor grade, the risk of
breast cancer death was positively associated with the Recur-
rence Score (continuous variable in 50-unit increments)
among ER-negative patients (relative risk 6.2, 95% CI 1.2–
31.8). Risk for death was also strongly associated with the
proliferation gene group (relative risk 5.1, 95% CI 2.0–13.5).
For some individual genes, associations appeared to be more
strongly positive in the ER-negative than in the ER-positive
patients (that is, Cyclin B1, Ki-67, STK15, survivin). For a few
genes, associations were in different directions for ER-nega-
tive and ER-positive patients (that is, BAG1, GSTM1, PgR).
Note that estimates for ER-negative patients were often impre-
cise because of small numbers.
Absolute risk of breast cancer death at 10 years: ER-
positive patients
The risks for breast cancer death at 10 years for ER-positive
patients treated with tamoxifen were 2.8% (95% CI 1.7–
3.9%), 10.7% (95% CI 6.3–14.9%), and 15.5% (95% CI
7.6–22.8%) for patients with Recurrence Score values in the
low, intermediate, and high risk categories, respectively (Table
5). Categories based on tumor size and/or grade identified a
Tumor grade (110 cases and 251 controls)
Well 15% 33% 5.5 (3.4–7.4)
Moderate 49% 52% 11.2 (8.6–13.8)
Poor 35% 15% 22.5 (15.9–28.6)
Tumor size and grade (110 cases and 251 controls)
≤2 cm and well or ≤1 cm and moderate 27% 50% 6.2 (4.3–8.0)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 45% 37% 14.2 (10.8–17.4)
>2 cm and moderate/poor 27% 13% 19.1 (13.2–24.7)
Recurrence Score, tumor size and grade
Recurrence Score low <18 (40 cases and 160 controls)
≤2 cm and well or ≤1 cm and moderate 35% 63% 3.0 (1.7–4.3)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 48% 31% 11.0 (7.0–14.8)
>2 cm and moderate/poor 17% 6% 20.2 (6.1–32.2)
Recurrence Score intermediate 18–30 (32 cases and 47 controls)
≤2 cm and well or ≤1 cm and moderate 34% 38% 17.0 (8.2–24.9)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 38% 34% 20.9 (10.2–30.4)
>2 cm and moderate/poor 28% 28% 22.0 (9.3–32.9)
Recurrence Score high ≥31 (38 cases and 44 controls)
≤2 cm and well or ≤1 cm and moderate 13% 14% 25.0 (7.9–39.0)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 50% 59% 21.0 (13.8–27.5)
>2 cm and moderate/poor 37% 27% 25.3 (15.1–34.3)
CI, confidence interval; ER, estrogen receptor.
Table 5 (Continued)
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set of patients at similarly low risk of breast cancer death,
although the Recurrence Score was able to identify a substan-
tially larger subgroup of patients. For example, 63% of the con-
trols were identified as low risk by the Recurrence Score,
whereas only 31% of controls had a tumor less than 1 cm.
Cross-classifying patients by Recurrence Score and tumor
size and grade resulted in very imprecise estimates (that is,
large CIs). Nonetheless, results suggest that among patients
with Recurrence Score values categorized as low risk, tumor
size and grade provide additional risk prediction information.
For ER-positive patients not treated with tamoxifen, the abso-
lute risks for death at 10 years were higher than those for ER-
positive patients treated with tamoxifen. The risks for breast
cancer death were 6.2% (95% CI 4.5–7.9%), 17.8% (95% CI
11.8–23.3%), and 19.9% (95% CI 14.2–25.2%) for patients
in the low, intermediate, and high risk Recurrence Score
groups, respectively. Again, when cross-classifying patients
by Recurrence Score and tumor size and grade, an improve-
ment in risk prediction was suggested primarily for those with
Recurrence Score values categorized as low risk.
Discussion
In this large, population-based study of lymph node-negative
patients not treated with chemotherapy, we found that the
Recurrence Score was strongly associated with risk of breast
cancer death among ER-positive patients treated with
tamoxifen. We also found that the Recurrence Score was
strongly associated with risk of breast cancer death among
ER-positive patients not treated with tamoxifen and among ER-
negative patients. In addition, we found that these associa-
tions remained after accounting for tumor size and grade, and
that the Recurrence Score was able to identify a larger subset
of patients with low risk of breast cancer death than was pos-
sible with either of these standard prognostic indicators.
Several limitations should be considered when interpreting our
results. We lacked ER status from the medical record for a
substantial proportion of patients, and we therefore classified
ER status based on gene expression. However, the estimates
of relative risk were not materially changed when analyses
were restricted to the 84% of patients with ER status from the
charts (data not shown). Because of the diagnosis years of the
study, only approximately 30% of patients were treated with
tamoxifen. Although this is consistent with what has been
reported for other patient populations during this period [27],
it limited the numbers of tamoxifen-treated patients for analy-
sis. Given that the cases and controls were matched with
respect to tamoxifen treatment, we could not directly examine
whether the Recurrence Score is able to identify patients who
are likely to respond to tamoxifen therapy. We did find a
stronger association between the Recurrence Score and risk
of breast cancer death among patients treated with tamoxifen
than among those untreated with tamoxifen, suggesting that
the Recurrence Score captures response to tamoxifen therapy
as well as prognosis. This is most likely explained by the fact
that the expression of ER-related genes was more strongly
associated with breast cancer-specific mortality in the
tamoxifen-treated patients than in those not treated with
tamoxifen (Figure 2), and is also consistent with the estab-
lished relationship between ER status of the tumor (by ligand
binding or immunohistochemistry assay) and response to
tamoxifen [4,28]. Our results are also consistent with findings
from a study conducted among participants of the NSABP B-
14 clinical trial, which randomized patients to tamoxifen versus
placebo [29]. In this population, the tamoxifen benefit varied by
Recurrence Score and was greatest for those with low Recur-
rence Score values. As expected, the strong association
between the quantitative expression of the ER gene and
tamoxifen benefit was largely responsible for this finding.
Currently, adjuvant hormonal and/or cytotoxic chemotherapy
are recommended for most women with early-stage invasive
breast cancer. Treatment decisions are based on axillary node
status, age, tumor size, histologic tumor type, tumor grade,
hormone receptor status (ER, PgR), and coexisting medical
conditions [4]. Hormonal therapy is recommended for nearly
all women with ER-positive tumors. Although tamoxifen is gen-
erally well tolerated, a significant proportion of women experi-
ence hot flashes and leg cramps, and up to 20% do not
complete a 5-year course of tamoxifen therapy [30-32].
Despite its potential for serious adverse effects [33], cytotoxic
chemotherapy has been recommended for most women with
lymph node-positive disease and for node-negative patients
with tumors greater than 1 cm or with unfavorable pathology
[4-6]. Very little information is available to support the use of
other clinical or biologic factors in selecting patients for adju-
vant chemotherapy [4]. Most patients with node-negative dis-
ease who receive chemotherapy will not derive benefit,
because they would not go on to have a recurrence even with-
out such treatment. New prognostic and predictive tests are
needed to better individualize therapy and confine systemic
treatment, especially cytotoxic chemotherapy, to those
patients who are most likely to benefit.
A growing number of studies suggest that multigene expres-
sion assays may be able to provide important prognostic and/
or predictive information for breast cancer patients [34-42]. A
variety of approaches and technologies are being used to
select genes and characterize expression (for example, cDNA
microarray chips, RT-PCR) in different types of pathology
specimens (for example, fresh frozen tissue, formalin-fixed par-
affin embedded tissue). No matter what the approach or tech-
nology, multiple, well conducted confirmatory studies using
standardized methodologies will be needed before the clinical
usefulness of any of these assays can be established.
This is the third study to evaluate the performance of the
Recurrence Score among patients not treated with systemic
chemotherapy [12,13]. The three studies used identical pre-Available online http://breast-cancer-research.com/content/8/3/R25
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specified scores and laboratory methods and were conducted
among patients who were independent of those used for gene
selection and Recurrence Score algorithm development. The
results of the first study, conducted by Esteva and coworkers
[13], differ substantially from our results and from those of the
NSABP B-14 study [12]. In that study no association was
found between the Recurrence Score and risk for distant
recurrence among a series of 149 node-negative patients who
were treated without adjuvant hormonal therapy or chemother-
apy at the MD Anderson Cancer Center between 1978 and
1995, who had potentially 5 or more years of follow up, and for
whom archived tissue was available. In contrast to the NSABP
B-14 study, patients in the study conducted by Esteva and
coworkers were not treated with tamoxifen. In contrast to our
study, the outcome of interest was distant recurrence instead
of breast cancer death. Although these may explain some of
the differences observed, it is also possible that the study by
Esteva and coworkers included a nonrepresentative group of
patients. Patients with poorly differentiated tumors had better
prognosis than those with well differentiated tumors, and there
was a suggestion that patients with ER-negative tumors did
better than those with ER-positive tumors.
Our relative risk estimates for the Recurrence Score in ER-
positive, tamoxifen-treated patients are generally quite similar
to those observed in the NSABP B-14 study. Relative risks
associated with expression of individual genes were also very
similar. In the NSABP B-14 study, the 10-year risk of breast
cancer death was 3.1% (95% CI 1.2–5.0%) in the low risk
group, 12.2% (95% CI 6.7–17.6%) in the intermediate risk
group, and 27.0% (95% CI 20.4–33.6%) in the high risk
group. Although very similar to our findings for the low and
intermediate risk groups, the 10-year risk for the NSABP B-14
high risk group was higher than ours. Patients in the two stud-
ies had a comparable age distribution, and although those in
the NSABP B-14 study were more likely to have larger tumors,
their tumors were also more likely to be well differentiated.
Therefore, there is uncertainty regarding the extent to which
differences in the distribution of prognostic factors in the two
study populations may explain the difference observed in
absolute risk estimates for the high risk group. In the Kaiser
population, tumor size and tumor grade remained statistically
significantly associated with risk of breast cancer death in
most multivariate models that also included the Recurrence
Score, whereas only tumor grade remained independently
associated with risk in the NSABP B-14 study. Tumor size was
determined by pathology in the Kaiser study and by clinical
examination in the NSABP B-14 study. Clinical examination of
tumor size is generally less accurate and could have resulted
in attenuated relative risk estimates.
Conclusion
The Recurrence Score has now been shown to be strongly
associated with risk of breast cancer-specific mortality among
lymph node-negative, ER-positive, tamoxifen-treated patients
participating in a clinical trial and among similar patients from
the community setting. In both study populations, the Recur-
rence Score was able to identify a large subset of patients
(approximately 50% or more) who were at very low risk of
breast cancer death at 10 years. In both studies it was also
observed that although the Recurrence Score was correlated
with tumor size and grade, there were a number of patients
with large and/or moderately or poorly differentiated tumors
with low risk Recurrence Score values. Results from our study,
and to a lesser extent the NSABP B-14 study, suggest that
combining Recurrence Score, tumor grade, and tumor size
provides better risk classification than any one of these factors
alone. Other studies, either retrospective or prospective, will
be needed to confirm our findings among lymph node-nega-
tive, ER-positive patients not treated with tamoxifen and
among ER-negative patients. Two studies have been per-
formed [43,44] and others are ongoing to assess the relation-
ship between the Recurrence Score and the magnitude of
chemotherapy benefit. Areas for future research also include
the examination of whether the Recurrence Score assay pro-
vides prognostic or predictive information for patients treated
with other hormonal agents or for patients with node-positive
breast cancer, whether test performance can be further opti-
mized by even more individualized dissection techniques, and
whether the inclusion of additional genes or the inclusion of
standard measures (tumor size, grade) may enhance risk pre-
diction overall or for selected patient subgroups.
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